All patients
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
anti-inflammatoty and immuno-therapy in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results ConPlas-19, 2020 0.56 [0.20; 1.57]
DAWN-Plasma, 2021 0.61 [0.24; 1.55]
NCT04397757, 2021 0.47 [0.04; 5.45]
Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
0.82 [0.42 ; 1.61 ] ConPlas-19, 2020, DAWN-Plasma, 2021, NCT04397757, 2021, Sekine (PLACOVID), 2021 4 24% 1,072 moderate not evaluable death D28detailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
Amra, 2021 0.47 [0.12; 1.93]
ASCOT, 2021 0.60 [0.06; 5.99]
Bennett-Guerrero, 2021 0.86 [0.24; 3.11]
CAN-COVID, 2020 0.67 [0.30; 1.50]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.12 [0.86; 1.46]
ConPlas-19, 2020 0.49 [0.20; 1.19]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-ANA-1, 2021 0.91 [0.38; 2.19]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
Davoudi-Monfared, 2020 0.30 [0.11; 0.83]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
Gharebaghi, 2020 0.00 [0.00; 0.09]
GLUCOCOVID, 2020 0.63 [0.25; 1.60]
Horby, 2021 1.01 [0.93; 1.10]
ITAC, 2022 0.80 [0.42; 1.52]
Jamaati, 2021 1.19 [0.38; 3.72]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Kirenga, 2021 1.25 [0.46; 3.39]
Lanzoni, 2021 0.14 [0.02; 0.96]
Li, 2020 0.59 [0.22; 1.59]
LIFESAVER, 2021 2.00 [0.16; 24.66]
Menichetti, 2021 0.75 [0.37; 1.53]
Metcovid, 2020 0.92 [0.67; 1.28]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PICP19 (Ray), 2020 0.67 [0.30; 1.51]
PLACID, 2020 1.04 [0.66; 1.63]
PLACO-COVID, 2021 1.71 [0.72; 4.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
REMAP-CAP, fixed 7-day course, 2020 1.03 [0.54; 1.98]
REMAP-CAP, shock-dependent course, 2020 1.10 [0.58; 2.10]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.59 [0.33; 1.06]
Sakoulas, 2020 0.29 [0.03; 3.13]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.56 [0.34; 7.13]
Tang X, 2020 0.98 [0.93; 1.02]
TOCOVID, 0 0.99 [0.02; 50.02]
Veiga, 2021 2.70 [0.92; 7.92]
0.88 [0.83 ; 0.94 ] ACTT-2 (Kalil), 2020, AlQahtani, 2020, Aman, 2021, Amra, 2021, ASCOT, 2021, Bennett-Guerrero, 2021, CAN-COVID, 2020, Co-CLARITY, 2021, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Davoudi-Monfared, 2020, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Gharebaghi, 2020, GLUCOCOVID, 2020, Horby, 2021, ITAC, 2022, Jamaati, 2021, Kalil (ACTT-3), 2021, Kirenga, 2021, Lanzoni, 2021, Li, 2020, LIFESAVER, 2021, Menichetti, 2021, Metcovid, 2020, NCT04377750 (HMO-0224-20), 0, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04528368, 2021, NCT04577534 (COVIDSTORM), 0, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PICP19 (Ray), 2020, PLACID, 2020, PLACO-COVID, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Raman, 2021, RECOVER, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Tabarsi, 2020, Talaschian, 2021, Tang X, 2020, TOCOVID, 0, Veiga, 2021 79 29% 64,437 moderate critical death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
COLCHIVID, 2021 0.83 [0.35; 1.95]
GLUCOCOVID, 2020 0.68 [0.37; 1.25]
Lopardo, 2021 0.65 [0.35; 1.22]
PLACID, 2020 1.07 [0.73; 1.57]
0.88 [0.68 ; 1.13 ] BACC Bay Tocilizumab Trial, 2020, COLCHIVID, 2021, GLUCOCOVID, 2020, Lopardo, 2021, PLACID, 2020 5 0% 1,010 moderate not evaluable deathsdetailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
ASCOT, 2021 0.60 [0.06; 5.99]
BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
CAN-COVID, 2020 0.67 [0.30; 1.50]
CAPE-COVID, 2020 0.45 [0.20; 1.02]
CAPSID, 2021 0.84 [0.28; 2.50]
CCAP-2, 2021 2.03 [0.61; 6.77]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCHIVID, 2021 0.69 [0.20; 2.40]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59]
CONFIDENT, 2020 0.84 [0.52; 1.37]
ConPlas-19, 2020 0.46 [0.19; 1.15]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COP-COVID-19, 2021 0.96 [0.36; 2.56]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-ANA-1, 2021 0.97 [0.46; 2.04]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
CPC-SARS, 2021 0.04 [0.01; 0.26]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
DEVENT, 0 0.47 [0.22; 1.00]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Edalatifard, 2020 0.29 [0.15; 0.56]
EMPACTA, 2020 1.13 [0.54; 2.40]
Esquivel-Moynelo, 2020 1.10 [0.02; 57.31]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
Fu, 2020 1.00 [0.02; 51.66]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
Gharebaghi, 2020 0.00 [0.00; 0.09]
GLUCOCOVID, 2020 0.63 [0.25; 1.60]
GRECCO-19, 2020 0.21 [0.02; 1.97]
Hamed, 2021 1.83 [0.16; 21.66]
Holm K, 2021 0.49 [0.08; 2.89]
Horby, 2021 1.01 [0.93; 1.10]
ILBS-COVID-02 (Bajpai M), 2020 3.82 [0.35; 41.96]
ITAC, 2022 0.80 [0.42; 1.52]
Jamaati, 2021 1.19 [0.38; 3.72]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Kirenga, 2021 1.25 [0.46; 3.39]
Kumar, 2021 0.06 [0.00; 1.35]
LACCPT, 2021 1.17 [0.58; 2.36]
Lanzoni, 2021 0.11 [0.01; 0.93]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
Li, 2020 0.59 [0.22; 1.59]
Libster, 2020 0.50 [0.09; 2.71]
LIFESAVER, 2021 2.00 [0.16; 24.66]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
Lopardo, 2021 0.57 [0.24; 1.37]
Lopes MIF, 2020 1.06 [0.02; 56.61]
Menichetti, 2021 0.75 [0.37; 1.53]
Metcovid, 2020 0.92 [0.67; 1.28]
Murugesan, 2022 1.00 [0.02; 51.41]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
NCT04385199, 2021 0.75 [0.15; 3.77]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04442191, 2021 0.11 [0.00; 143.68]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PICP19 (Ray), 2020 0.67 [0.30; 1.51]
PLACID, 2020 1.04 [0.66; 1.63]
PLACO-COVID, 2021 1.71 [0.72; 4.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
Rasheed, 2020 0.13 [0.01; 1.09]
RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2021 0.85 [0.76; 0.95]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
REMAP-CAP sarilumab, 2021 0.51 [0.25; 1.07]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
Sakoulas, 2020 0.29 [0.03; 3.13]
Salehzadeh, 2020 1.00 [0.02; 51.41]
sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80]
sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55]
SOLIDARITY (interferon), 2020 1.16 [0.96; 1.40]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
SPRINTER, 2022 0.79 [0.38; 1.66]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.25 [0.30; 5.14]
Tang X, 2020 0.98 [0.93; 1.02]
TOCOVID, 0 0.99 [0.02; 50.02]
Veiga, 2021 2.70 [0.92; 7.92]
0.86 [0.82 ; 0.91 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, AlQahtani, 2020, Aman, 2021, ASCOT, 2021, BACC Bay Tocilizumab Trial, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, CAN-COVID, 2020, CAPE-COVID, 2020, CAPSID, 2021, CCAP-2, 2021, Co-CLARITY, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, COLCHIVID, 2021, COLCOVID, 2021, CONCOR-1, 2021, ConCOVID (Gharbharan et al.), 2020, CONFIDENT, 2020, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COP-COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, CP-COVID-19, 2021, CPC-SARS, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, DEVENT, 0, DEXA-COVID19, 2020, Edalatifard, 2020, EMPACTA, 2020, Esquivel-Moynelo, 2020, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, Fu, 2020, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Gharebaghi, 2020, GLUCOCOVID, 2020, GRECCO-19, 2020, Hamed, 2021, Holm K, 2021, Horby, 2021, ILBS-COVID-02 (Bajpai M), 2020, ITAC, 2022, Jamaati, 2021, Kalil (ACTT-3), 2021, Kirenga, 2021, Kumar, 2021, LACCPT, 2021, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, Libster, 2020, LIFESAVER, 2021, LIVE-AIR (Temesgen), 2021, Lopardo, 2021, Lopes MIF, 2020, Menichetti, 2021, Metcovid, 2020, Murugesan, 2022, NCT04377750 (HMO-0224-20), 0, NCT04385199, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04442191, 2021, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04528368, 2021, NCT04577534 (COVIDSTORM), 0, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PICP19 (Ray), 2020, PLACID, 2020, PLACO-COVID, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, Rasheed, 2020, RCT-TCZ-COVID-19, 2021, RECOVER, 2021, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, Sakoulas, 2020, Salehzadeh, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, SAVE-MORE, 2021, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, SOLIDARITY (interferon), 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, SPRINTER, 2022, Steroids-SARI, 2020, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tabarsi, 2020, Talaschian, 2021, Tang X, 2020, TOCOVID, 0, Veiga, 2021 134 32% 90,934 moderate critical deaths (time to event analysis only)detailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConPlas-19, 2020 0.46 [0.19; 1.15]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Edalatifard, 2020 0.29 [0.15; 0.56]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lanzoni, 2021 0.11 [0.01; 0.93]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
PlasmAr, 2020 0.93 [0.47; 1.85]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
Talaschian, 2021 1.25 [0.30; 5.14]
0.80 [0.68 ; 0.93 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTT-2 (Kalil), 2020, Baldeon, 2022, Bennett-Guerrero, 2021, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, COV-BARRIER, 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Davoudi-Monfared, 2020, DAWN-Plasma, 2021, Edalatifard, 2020, Kalil (ACTT-3), 2021, Lanzoni, 2021, LIVE-AIR (Temesgen), 2021, PlasmAr, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, Talaschian, 2021 23 44% 11,670 moderate low clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
CAPSID, 2021 0.63 [0.29; 1.40]
CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58]
ConPlas-19, 2020 1.00 [0.65; 1.53]
CONTAIN COVID-19, 2021 0.94 [0.75; 1.18]
CORIMUNO-ANA-1, 2021 0.89 [0.42; 1.92]
CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
COV-BARRIER, 2021 1.12 [0.58; 2.16]
EMPACTA, 2020 0.55 [0.33; 0.92]
Esquivel-Moynelo, 2020 2.29 [0.20; 26.58]
GRECCO-19, 2020 0.11 [0.01; 1.08]
Kirenga, 2021 0.91 [0.38; 2.17]
Libster, 2020 0.52 [0.29; 0.94]
PLACID, 2020 1.04 [0.54; 1.99]
RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
Shu, 2020 0.27 [0.01; 5.58]
Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77]
SPRINTER, 2022 0.69 [0.43; 1.11]
STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
Tang X, 2020 1.00 [0.13; 7.45]
0.72 [0.60 ; 0.86 ] BACC Bay Tocilizumab Trial, 2020, CAPSID, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, COV-BARRIER, 2021, EMPACTA, 2020, Esquivel-Moynelo, 2020, GRECCO-19, 2020, Kirenga, 2021, Libster, 2020, PLACID, 2020, RCT-TCZ-COVID-19, 2021, SAVE-MORE, 2021, Shu, 2020, Soin AS (COVINTOC), 2021, SPRINTER, 2022, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020 24 44% 5,699 moderate low clinical improvementdetailed results ACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20]
ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
CAN-COVID, 2020 1.39 [0.76; 2.54]
CAPSID, 2021 1.58 [0.71; 3.49]
ConPlas-19, 2020 0.95 [0.60; 1.52]
COV-BARRIER, 2021 1.25 [1.04; 1.50]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
Dongsheng Wang, 2020 2.37 [0.40; 13.96]
Edalatifard, 2020 12.00 [2.39; 60.20]
EMPACTA, 2020 1.15 [0.90; 1.47]
ITAC, 2022 1.06 [0.77; 1.45]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Li, 2020 1.40 [0.79; 2.49]
Lopardo, 2021 1.61 [0.75; 3.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
REMAP-CAP sarilumab, 2021 1.76 [1.12; 2.78]
REMAP-CAP, fixed 7-day course, 2020 1.43 [0.91; 2.26]
REMAP-CAP, shock-dependent course, 2020 1.22 [0.76; 1.95]
sarilumab phase 2 high dose, 0 2.09 [1.00; 4.36]
sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
Tang X, 2020 1.04 [0.67; 1.62]
1.20 [1.10 ; 1.30 ] ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, Bennett-Guerrero, 2021, CAN-COVID, 2020, CAPSID, 2021, ConPlas-19, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Davoudi-Monfared, 2020, Dongsheng Wang, 2020, Edalatifard, 2020, EMPACTA, 2020, ITAC, 2022, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Li, 2020, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020, Tang X, 2020 37 42% 11,352 moderate critical clinical improvement (14-day)detailed results ACTT-2 (Kalil), 2020 1.30 [1.03; 1.64]
COV-BARRIER, 2021 1.28 [1.05; 1.56]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
Li, 2020 2.27 [0.90; 5.72]
Pandit, 2021 8.77 [0.94; 81.67]
REMAP-CAP sarilumab, 2021 1.86 [1.20; 2.87]
REMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03]
REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
Tang X, 2020 1.33 [0.57; 3.11]
1.32 [1.11 ; 1.56 ] ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, Kalil (ACTT-3), 2021, Li, 2020, Pandit, 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Shashi Bhushan, 2021, Shu, 2020, Tang X, 2020 12 38% 5,087 moderate critical clinical improvement (28-day)detailed results Bennett-Guerrero, 2021 1.02 [0.25; 4.20]
COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Li, 2020 1.42 [0.65; 3.10]
O’Donnell, 2021 1.38 [0.73; 2.61]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 3.68 [0.18; 75.54]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 3.15 [1.39; 7.14]
1.48 [1.08 ; 2.03 ] Bennett-Guerrero, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Li, 2020, O’Donnell, 2021, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020 11 44% 1,326 moderate critical clinical improvement (7-day)detailed results ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ITAC, 2022 1.06 [0.77; 1.45]
Li, 2020 0.98 [0.27; 3.58]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
Shu, 2020 6.72 [1.50; 30.07]
1.29 [0.82 ; 2.01 ] ACTIV-3/TICO LY-CoV555 , 2020, ITAC, 2022, Li, 2020, Shashi Bhushan, 2021, Shu, 2020 5 61% 1,265 moderate not evaluable clinical improvement (time to event analysis only)detailed results ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
ConPlas-19, 2020 0.95 [0.60; 1.52]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
EMPACTA, 2020 1.15 [0.90; 1.47]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
Li, 2020 1.40 [0.79; 2.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
Rahmani, 2020 3.41 [1.33; 8.73]
sarimulab phase 2 low dose, 0 0.96 [0.53; 1.73]
SPRINTER, 2022 1.02 [0.81; 1.28]
Tang X, 2020 1.04 [0.67; 1.62]
1.09 [1.02 ; 1.16 ] ACTT-2 (Kalil), 2020, Bennett-Guerrero, 2021, ConPlas-19, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, EMPACTA, 2020, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, sarimulab phase 2 low dose, 0, SPRINTER, 2022, Tang X, 2020 17 0% 4,506 low low death or ventilationdetailed results ACTT-2 (Kalil), 2020 0.69 [0.50; 0.95]
BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
CAPE-COVID, 2020 0.71 [0.37; 1.35]
COLCOVID, 2021 0.83 [0.67; 1.02]
CONCOR-1, 2021 1.16 [0.94; 1.43]
ConPlas-19, 2020 0.94 [0.86; 1.02]
CORIMUNO-ANA-1, 2021 0.97 [0.62; 1.52]
CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
DAWN-Plasma, 2021 1.01 [0.64; 1.59]
EMPACTA, 2020 0.56 [0.32; 0.97]
LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
Menichetti, 2021 0.88 [0.59; 1.32]
RECOVERY, 2021 0.85 [0.78; 0.93]
RECOVERY, 2022 0.90 [0.81; 0.99]
RECOVERY (colchicine), 2021 1.02 [0.96; 1.09]
RECOVERY (plasma), 2021 0.99 [0.93; 1.05]
RECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92]
RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01]
REMAP-CAP, fixed 7-day course, 2020 2.74 [1.16; 6.46]
REMAP-CAP, shock-dependent course, 2020 1.24 [0.55; 2.78]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
Rutgers, 2021 0.65 [0.43; 0.99]
sarilumab phase 2 high dose, 0 0.39 [0.18; 0.82]
sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44]
SOLIDARITY (interferon), 2020 1.05 [0.90; 1.23]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
SPRINTER, 2022 0.85 [0.45; 1.61]
STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97]
Synairgen SG016, 2020 0.38 [0.09; 1.63]
Veiga, 2021 1.54 [0.65; 3.63]
0.90 [0.85 ; 0.95 ] ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, CAPE-COVID, 2020, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, DAWN-Plasma, 2021, EMPACTA, 2020, LIVE-AIR (Temesgen), 2021, Menichetti, 2021, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, SOLIDARITY (interferon), 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, SPRINTER, 2022, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Veiga, 2021 31 55% 54,874 moderate critical hospital dischargedetailed results ACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20]
CAPE-COVID, 2020 1.67 [0.87; 3.19]
COLCHIVID, 2021 1.13 [0.76; 1.67]
ConPlas-19, 2020 1.02 [0.82; 1.28]
Davoudi-Monfared, 2020 1.96 [0.76; 5.03]
DAWN-Plasma, 2021 1.06 [0.87; 1.30]
EMPACTA, 2020 1.16 [0.90; 1.49]
Rahmani, 2020 3.44 [0.64; 18.49]
RECOVERY (colchicine), 2021 0.98 [0.94; 1.03]
RECOVERY (plasma), 2021 0.99 [0.92; 1.07]
RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31]
RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
SPRINTER, 2022 1.06 [0.89; 1.27]
Synairgen SG016, 2020 1.63 [0.61; 4.35]
1.07 [1.01 ; 1.14 ] ACTIV-3/TICO LY-CoV555 , 2020, CAPE-COVID, 2020, COLCHIVID, 2021, ConPlas-19, 2020, Davoudi-Monfared, 2020, DAWN-Plasma, 2021, EMPACTA, 2020, Rahmani, 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, Rosas (REMDACTA), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, SPRINTER, 2022, Synairgen SG016, 2020 16 52% 36,615 moderate critical hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable mechanical ventilationdetailed results ACTT-2 (Kalil), 2020 0.64 [0.44; 0.93]
AlQahtani, 2020 0.67 [0.22; 2.02]
CAPE-COVID, 2020 0.95 [0.44; 2.04]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COPLA-II trial, 2020 0.58 [0.37; 0.92]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Davoudi-Monfared, 2020 0.72 [0.29; 1.76]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.85 [0.68; 1.06]
GRECCO-19, 2020 0.17 [0.02; 1.48]
Hamed, 2021 3.15 [0.57; 17.48]
Holm K, 2021 0.39 [0.01; 12.68]
Jamaati, 2021 1.38 [0.45; 4.20]
Metcovid, 2020 1.19 [0.56; 2.49]
NCT04397757, 2021 0.41 [0.13; 1.35]
O’Donnell, 2021 1.50 [0.47; 4.82]
PLACID, 2020 0.99 [0.54; 1.81]
PlasmAr, 2020 0.86 [0.39; 1.93]
Rahmani, 2020 0.29 [0.05; 1.56]
RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69]
RECOVERY, 2022 0.87 [0.74; 1.02]
RECOVERY (colchicine), 2021 1.04 [0.93; 1.16]
RECOVERY (plasma), 2021 0.98 [0.88; 1.09]
RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95]
Rutgers, 2021 0.65 [0.35; 1.24]
Sakoulas, 2020 0.19 [0.03; 1.11]
sarilumab phase 2 high dose, 0 0.27 [0.10; 0.71]
sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
Shu, 2020 0.59 [0.02; 14.04]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38]
Tabarsi, 2020 1.49 [0.59; 3.78]
0.83 [0.74 ; 0.93 ] ACTT-2 (Kalil), 2020, AlQahtani, 2020, CAPE-COVID, 2020, COL-COVID (Pascual-Figal), 2021, COPLA-II trial, 2020, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, Hamed, 2021, Holm K, 2021, Jamaati, 2021, Metcovid, 2020, NCT04397757, 2021, O’Donnell, 2021, PLACID, 2020, PlasmAr, 2020, Rahmani, 2020, RCT-TCZ-COVID-19, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY dexamethasone, 2020, Rutgers, 2021, Sakoulas, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, SAVE-MORE, 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, Tabarsi, 2020 35 34% 40,792 moderate critical mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
DAWN-Plasma, 2021 1.08 [0.65; 1.80]
0.97 [0.62 ; 1.52 ] CP-COVID-19, 2021, DAWN-Plasma, 2021 2 0% 583 moderate not evaluable radiologic improvement (14-day)detailed results Jamaati, 2021 4.89 [1.15; 20.79]
Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28]
Tabarsi, 2020 2.33 [0.45; 12.00]
3.02 [1.77 ; 5.14 ] Jamaati, 2021, Rashad (CLARI vs SoC), 2021, Tabarsi, 2020 3 0% 332 moderate not evaluable Recovery (time to event analysis only)detailed results SPRINTER, 2022 1.02 [0.81; 1.28]
1.02 [0.81 ; 1.28 ] SPRINTER, 2022 1 0% 623 NA not evaluable viral clearance detailed results CP-COVID-19, 2021 1.12 [0.16; 7.84]
Esquivel-Moynelo, 2020 3.26 [1.53; 6.95]
Jagannathan, 2020 0.81 [0.56; 1.18]
Pandit, 2021 2.33 [0.55; 9.83]
Raman, 2021 36.42 [10.85; 122.18]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
Tang X, 2020 1.78 [1.06; 3.00]
2.59 [1.21 ; 5.54 ] CP-COVID-19, 2021, Esquivel-Moynelo, 2020, Jagannathan, 2020, Pandit, 2021, Raman, 2021, Salman, 2020, Shashi Bhushan, 2021, Tang X, 2020 8 84% 780 moderate not evaluable viral clearance (time to event analysis only)detailed results Esquivel-Moynelo, 2020 3.26 [1.53; 6.95]
Jagannathan, 2020 0.81 [0.56; 1.18]
Tang X, 2020 1.78 [1.06; 3.00]
1.59 [0.73 ; 3.49 ] Esquivel-Moynelo, 2020, Jagannathan, 2020, Tang X, 2020 3 85% 269 moderate not evaluable viral clearance by day 14detailed results CP-COVID-19, 2021 1.51 [0.33; 6.94]
Esquivel-Moynelo, 2020 5.90 [0.28; 122.94]
Kirenga, 2021 0.95 [0.76; 1.19]
Pandit, 2021 10.23 [1.12; 93.35]
Raman, 2021 36.42 [10.85; 122.18]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
1.37 [0.12 ; 16.35 ] CP-COVID-19, 2021, Esquivel-Moynelo, 2020, Kirenga, 2021, Pandit, 2021, Raman, 2021, Shashi Bhushan, 2021 6 97% 1,747 moderate not evaluable viral clearance by day 7detailed results Esquivel-Moynelo, 2020 3.09 [1.04; 9.17]
Kirenga, 2021 0.87 [0.65; 1.16]
Pandit, 2021 2.33 [0.55; 9.83]
PLACID, 2020 1.20 [1.00; 1.44]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.45 [0.97 ; 2.15 ] Esquivel-Moynelo, 2020, Kirenga, 2021, Pandit, 2021, PLACID, 2020, Salman, 2020, Shashi Bhushan, 2021 6 66% 844 moderate not evaluable ICU admissiondetailed results COL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69]
COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.99 [0.56; 1.75]
GLUCOCOVID, 2020 0.85 [0.27; 2.67]
Hamed, 2021 3.15 [0.57; 17.48]
Libster, 2020 0.33 [0.07; 1.58]
Lopardo, 2021 0.67 [0.35; 1.28]
Lopes MIF, 2020 1.06 [0.06; 18.45]
Rahmani, 2020 0.37 [0.14; 1.00]
Rutgers, 2021 0.96 [0.55; 1.68]
Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64]
Tabarsi, 2020 0.56 [0.18; 1.74]
Tang X, 2020 1.00 [0.13; 7.45]
0.79 [0.63 ; 0.99 ] COL-COVID (Pascual-Figal), 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GLUCOCOVID, 2020, Hamed, 2021, Libster, 2020, Lopardo, 2021, Lopes MIF, 2020, Rahmani, 2020, Rutgers, 2021, Soin AS (COVINTOC), 2021, Tabarsi, 2020, Tang X, 2020 16 0% 2,019 moderate low off oxygenationdetailed results Davoudi-Monfared, 2020 8.57 [1.43; 51.36]
ILBS-COVID-02 (Bajpai M), 2020 0.26 [0.02; 2.88]
sarilumab phase 2 high dose, 0 1.99 [0.95; 4.15]
sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21]
1.62 [0.67 ; 3.92 ] Davoudi-Monfared, 2020, ILBS-COVID-02 (Bajpai M), 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 4 58% 331 serious not evaluable recoverydetailed results ACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32]
ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37]
ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46]
COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
Lanzoni, 2021 3.46 [1.05; 11.35]
Synairgen SG016, 2020 2.19 [1.03; 4.67]
Talaschian, 2021 0.64 [0.14; 2.92]
1.17 [0.98 ; 1.39 ] ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020, COV-BARRIER (critically ill), 2022, Lanzoni, 2021, Synairgen SG016, 2020, Talaschian, 2021 7 25% 1,290 low not evaluable composite safety outcome detailed results ACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11]
1.56 [0.78 ; 3.11 ] ACTIV-3/TICO LY-CoV555 , 2020 1 0% 314 NA not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
CAN-COVID, 2020 0.73 [0.45; 1.19]
CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
CONCOR-1, 2021 1.27 [1.02; 1.58]
ConPlas-19, 2020 0.89 [0.43; 1.86]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Dongsheng Wang, 2020 0.91 [0.02; 47.31]
Edalatifard, 2020 0.81 [0.11; 6.17]
ITAC, 2022 0.98 [0.66; 1.46]
Jagannathan, 2020 1.00 [0.14; 7.34]
Lanzoni, 2021 0.10 [0.01; 0.69]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
O’Donnell, 2021 0.64 [0.35; 1.17]
Pandit, 2021 0.95 [0.02; 50.33]
PlasmAr, 2020 1.40 [0.78; 2.51]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
REMAP-CAP, fixed 7-day course, 2020 3.01 [0.33; 27.32]
REMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
Shi, 2020 1.08 [0.04; 32.96]
Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
1.05 [0.91 ; 1.20 ] BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, CONCOR-1, 2021, ConPlas-19, 2020, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Edalatifard, 2020, ITAC, 2022, Jagannathan, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, O’Donnell, 2021, Pandit, 2021, PlasmAr, 2020, Raman, 2021, REMAP-CAP (plasma), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 2021 27 18% 8,552 moderate low superinfectiondetailed results ACTT-2 (Kalil), 2020 0.50 [0.32; 0.79]
CAPE-COVID, 2020 0.81 [0.49; 1.34]
Davoudi-Monfared, 2020 2.41 [0.75; 7.73]
Metcovid, 2020 0.98 [0.65; 1.47]
Rahmani, 2020 0.18 [0.02; 1.59]
0.80 [0.50 ; 1.27 ] ACTT-2 (Kalil), 2020, CAPE-COVID, 2020, Davoudi-Monfared, 2020, Metcovid, 2020, Rahmani, 2020 5 61% 1,722 moderate not evaluable adverse eventsdetailed results COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08]
COLCHIVID, 2021 1.63 [0.67; 3.95]
COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Dongsheng Wang, 2020 9.64 [2.76; 33.75]
Esquivel-Moynelo, 2020 1.33 [0.45; 3.92]
Jagannathan, 2020 1.33 [0.63; 2.78]
Kirenga, 2021 1.13 [0.50; 2.58]
Lanzoni, 2021 0.18 [0.02; 1.95]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Pandit, 2021 1.68 [0.47; 5.97]
Raman, 2021 1.36 [0.56; 3.30]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Sakoulas, 2020 1.00 [0.02; 53.46]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Shi, 2020 0.88 [0.38; 2.03]
Shu, 2020 2.48 [0.05; 132.54]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87]
Veiga, 2021 1.65 [0.81; 3.37]
1.24 [1.04 ; 1.48 ] COL-COVID (Pascual-Figal), 2021, COLCHIVID, 2021, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Esquivel-Moynelo, 2020, Jagannathan, 2020, Kirenga, 2021, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Pandit, 2021, Raman, 2021, Rosas (REMDACTA), 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, Veiga, 2021 21 17% 2,901 moderate low 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-15 23:26 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525
- roots T: 290